IP Library › Granted Patent US 11,185,510
Granted Patent B2
US 11,185,510 · App. 16/543,102 · Granted Nov 30, 2021

Combinations of mRNAs encoding immune modulating polypeptides and uses thereof

Inventors: Joshua P. Frederick (Charlestown, MA); Ailin Bai (Newton, MA); Vladimir Presnyak (Manchester, NH); Stephen G. Hoge (Brookline, MA); Kerry Benenato (Sudbury, MA); Iain McFadyen (Arlington, MA); Ellalahewage Sathyajith Kumarasinghe (Harvard, MA); Susannah Hewitt (Jamaica Plain, MA)
Assignee: ModernaTX, Inc.
A61K9/5123A61K9/00A61K9/0019A61K9/1272A61K9/5146A61K31/7088A61K31/7115A61K38/177A61K38/1774A61K38/20A61K38/2006A61K38/208A61K38/2086A61K39/39A61K39/3955A61K45/06A61K48/00A61K48/005A61P35/00C07K14/54C07K14/545C07K14/5434C07K14/5443C07K14/5446C07K14/70575A61K2039/505A61K2039/51A61K2039/53A61K2039/54A61K2039/545A61K2039/585B82Y5/00C07K2319/00C12N15/88
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,185,510
App. No.
16/543,102
Granted
Nov 30, 2021
Kind
B2
Abstract

The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of combinations of immunomodulatory polynucleotides (e.g., mRNAs) encoding an immune response primer polypeptide (e.g., an interleukin 23 (IL-23) polypeptide or an interleukin 36γ (IL-36-gamma) polypeptide), and an immune response co-stimulatory signal polypeptide (e.g., an OX40L polypeptide).

Claims (26)

1. A lipid nanoparticle (LNP) comprising: (i) a first mRNA comprising an open reading frame (ORF) encoding a human IL-23 polypeptide and (ii) a second mRNA comprising an ORF encoding a human IL-36 gamma polypeptide, wherein the LNP comprises an ionizable amino lipid, a phospholipid, a sterol, and a PEG-modified lipid.

2. The lipid nanoparticle of claim 1 , wherein the IL-23 polypeptide comprises an IL-12p40 polypeptide operably linked, with or without a linker, to an IL-23p19 polypeptide.

3. The lipid nanoparticle of claim 1 , wherein the IL-23 polypeptide comprises an IL-12p40 polypeptide operably linked via a linker to an IL-23p19 polypeptide.

4. The lipid nanoparticle of claim 3 , wherein the linker is a Gly/Ser linker.

5. The lipid nanoparticle of claim 4 , wherein the IL-23 polypeptide comprises the amino acid sequence of SEQ ID NO: 140.

6. The lipid nanoparticle of claim 1 , wherein the IL-36 gamma polypeptide comprises an amino acid sequence selected from the group consisting of the amino acid sequence of SEQ ID NO: 10, the amino acid sequence of SEQ ID NO: 12, and the amino acid sequence of SEQ ID NO: 16.

7. The lipid nanoparticle of claim 1 , further comprising a third mRNA comprising an ORF encoding a human OX40L polypeptide.

8. The lipid nanoparticle of claim 7 , wherein the OX40L polypeptide comprises an amino acid sequence selected from the group consisting of the amino acid sequence of SEQ ID NO: 2, and the amino acid sequence of SEQ ID NO: 21.

9. The lipid nanoparticle of claim 8 , wherein the first mRNA comprises the amino acid sequence of SEQ ID NO: 140; (ii) the second mRNA comprises amino acid sequence of SEQ ID NO: 16; and (iii) the third mRNA comprises the amino acid sequence of SEQ ID NO: 21.

10. The lipid nanoparticle of claim 9 , wherein the first, second, and third mRNAs are formulated in the lipid nanoparticle at a mass ratio of IL-23:IL-36 gamma:OX40L of 1:2:1.

11. The lipid nanoparticle of claim 7 , wherein each of the first, second and third mRNAs comprise a 5′cap, a 5′untranslated region (UTR), a 3′UTR comprising a miR-122 binding site and a polyA tail.

12. The lipid nanoparticle of claim 7 , wherein each of the first, second and third mRNAs are fully modified with chemically-modified uridines.

13. The lipid nanoparticle of claim 1 , wherein the lipid nanoparticle comprises a molar ratio of about 20-60% ionizable amino lipid, about 5-25% phospholipid, about 25-55% sterol, and about 0.5-1.5% PEG-modified lipid.

14. The lipid nanoparticle of claim 1 , wherein the ionizable lipid comprises a compound having the formula:

15. The lipid nanoparticle of claim 1 , wherein the PEG lipid comprises PEG DMG.

16. The lipid nanoparticle of claim 1 , wherein the phospholipid comprises DSPC.

17. The lipid nanoparticle of claim 1 , wherein the structural lipid comprises cholesterol.

18. The lipid nanoparticle of claim 13 wherein the lipid nanoparticle comprises a molar ratio of 40-60% ionizable amino lipid, 8-16% phospholipid, 30-45% sterol, and 1-5% PEG modified lipid.

19. The lipid nanoparticle of claim 18 , wherein the lipid nanoparticle comprises a molar ratio of 40-60% Compound 18, 8-16% DSPC, 30-45% cholesterol, and 1-5% PEG DMG.

20. The lipid nanoparticle of claim 13 , wherein the lipid nanoparticle comprises a molar ratio of 45-65% ionizable amino lipid, 5-10% phospholipid, 25-40% sterol, and 0.5-5% PEG modified lipid.

21. The lipid nanoparticle of claim 20 , wherein the lipid nanoparticle comprises a molar ratio of 45-65% Compound 18, 5-10% DSPC, 25-40% cholesterol, and 0.5-5% PEG DMG.

22. The lipid nanoparticle of claim 9 , wherein the lipid nanoparticle comprises a molar ratio of about 20-60% ionizable amino lipid, about 5-25% phospholipid, about 25-55% sterol, and about 0.5-1.5% PEG-modified lipid.

23. The lipid nanoparticle of claim 22 , wherein the lipid nanoparticle comprises a molar ratio of 40-60% ionizable amino lipid, 8-16% phospholipid, 30-45% sterol, and 1-5% PEG modified lipid.

24. The lipid nanoparticle of claim 23 , wherein the lipid nanoparticle comprises a molar ratio of 40-60% Compound 18, 8-16% DSPC, 30-45% cholesterol, and 1-5% PEG DMG.

25. The lipid nanoparticle of claim 22 wherein the lipid nanoparticle comprises a molar ratio of 45-65% ionizable amino lipid, 5-10% phospholipid, 25-40% sterol, and 0.5-5% PEG modified lipid.

26. The lipid nanoparticle of claim 25 , wherein the lipid nanoparticle comprises a molar ratio of 45-65% Compound 18, 5-10% DSPC, 25-40% cholesterol, and 0.5-5% PEG DMG.

Assignments (2)
SECURITY INTEREST Recorded Nov 19, 2025
From: MODERNATX, INC.
To: ARES CAPITAL CORPORATION, AS AGENT
Reel/Frame 073634/0354 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 14, 2020
From: FREDERICK, JOSHUA; BAI, AILIN; PRESNYAK, VLADIMIR; HOGE, STEPHEN; BENENATO, KERRY; MCFADYEN, IAIN; KUMARASINGHE, ELLALAHEWAGE SATHYAJITH; HEWITT, SUSANNAH
To: MODERNATX, INC.
Reel/Frame 051509/0359 →